Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Pro-Dex, Inc. (PDEX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ...

Pro-Dex, Inc. ( PDEX ) is a contract manufacturer, primarily designing, developing, and manufacturing surgical devices for the medical device industry. The stock has been on a wild ride over the last year, trading as high as $70 and as low as $16. Despite a record performance forI am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I writ ...

Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 108.51%. A quarter ago, it was expected that this company would post earnings of $0.38 per share when it actually produced earnings of $0.61, delivering a surprise of 60.53%.Over the last four quarters, the company h ...

For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2025 THIRD QUARTER AND NINE-MONTH RESULTS Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 Operating expenses (which include selling, general and administrative, and research and development expenses) for the nine months ended March 31, 2025, increased 18% to $6.7 million from $5.6 million in the prior fiscal year's corresponding period, due primarily to an overall increase in personnel costs and legal fees. Our operating ...

——————— FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 0-14942 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRO-DEX, INC. (Exact name of registrant as specified in its charter) ——————— COLORADO 84-1261240 (State ...

Pro-Dex, Inc. (PDEX) shares ended the last trading session 5.1% higher at $66.92. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 28.9% gain over the past four weeks.The company's shares are in uptrend since March. The recent surge in price is likely due to continuation of the trend.This company is expected to post quarterly earnings of $0.47 per share in its upcoming report, which represents a year-over-year chang ...

文章核心观点 - Pro - Dex股价因投资者对其2025财年第三季度财报乐观预期而上涨 ，需关注后续盈利预测修正趋势；West Pharmaceutical Services盈利预测有变化且评级为卖出 [1][2][5] Pro - Dex公司情况 - 上一交易日股价飙升7.4% ，收于55.19美元 ，成交量可观 ，过去四周累计上涨49.8% [1] - 近期股价上涨归因于投资者对2025财年第三季度财报的乐观预期 ，此前第二季度营收同比增长33% ，营业利润增长247% [2] - 预计即将公布的财报中每股收益0.47美元 ，同比增长147.4% ，营收1770万美元 ，同比增长23.9% [3] - 过去30天该季度的每股收益共识预期未变 ，当前Zacks评级为1（强力买入） [4] West Pharmaceutical Services公司情况 - 上一交易日股价上涨0.6% ，收于221.50美元 ，过去一个月回报率为 - 2.4% [4] - 即将公布的财报每股收益共识预期过去一个月变化 - 5%至1.30美元 ，较去年同期变化 - 16.7% ，当前Zacks评级为4（卖出） [5] 行业情况 - 两家公司均属于Zacks医疗 - 牙科用品行业 [4]

Pro-Dex, Inc. (PDEX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

文章核心观点 - Pro - Dex本季度财报表现超预期，股价年初至今下跌，未来表现受管理层评论、盈利预期及行业前景影响，当前Zacks Rank为3（持有），同行业West Pharmaceutical Services待公布财报 [1][3][6] Pro - Dex财报情况 - 本季度每股收益0.61美元，超Zacks共识预期0.38美元，去年同期为0.14美元，盈利惊喜达60.53% [1] - 上一季度预期每股收益0.29美元，实际为0.75美元，盈利惊喜158.62% [1] - 过去四个季度，公司两次超共识每股收益预期 [2] - 截至2024年12月季度营收1679万美元，超Zacks共识预期21.69%，去年同期为1259万美元，过去四个季度两次超共识营收预期 [2] Pro - Dex股价表现 - 年初至今股价下跌约7.5%，而标准普尔500指数上涨2.7% [3] Pro - Dex未来展望 - 股价短期走势取决于管理层财报电话会议评论及未来盈利预期 [3] - 盈利前景可帮助投资者判断股票走向，包括当前季度共识盈利预期及预期变化 [4] - 近期盈利预测修正趋势与股价短期走势强相关，可通过Zacks Rank跟踪 [5] - 财报发布前盈利预测修正趋势喜忧参半，当前Zacks Rank为3（持有），预计短期内与市场表现一致 [6] - 未来需关注未来季度和本财年盈利预测变化，当前季度共识每股收益预期0.43美元，营收1570万美元，本财年共识每股收益预期2美元，营收6100万美元 [7] 行业情况 - Zacks行业排名中，医疗 - 牙科用品行业处于250多个Zacks行业后40%，研究显示排名前50%的行业表现优于后50%超两倍 [8] 同行业公司情况 - 同行业West Pharmaceutical Services待公布2024年12月季度财报，预计每股收益1.75美元，同比降4.4%，过去30天该季度共识每股收益预期未变 [9] - 预计营收7.3959亿美元，同比增1% [9]